Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Ruxolitinib With Artemether-lumefantrine

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 10, 2020

Primary Completion Date

November 17, 2020

Study Completion Date

November 17, 2020

Conditions
Malaria
Interventions
DRUG

20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)

Rux administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).

OTHER

20 mg/120 mg artemether-lumefantrine (AL) + Placebo

Placebo administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).

Trial Locations (1)

Unknown

Nucleus Network Brisbane, Brisbane

All Listed Sponsors
collaborator

Southern Star Research

INDUSTRY

collaborator

Nucleus Network Ltd

OTHER

lead

Medicines for Malaria Venture

OTHER